|By PR Newswire||
|December 12, 2012 07:24 PM EST||
RENO, Nev., Dec. 12, 2012 /PRNewswire/ -- First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech. "We look forward to productive developments regarding the regulatory advise, marketing and distribution resources of UniCorp Biotech", says Jim Holmes, Chairman and CEO of First Waning Systems. "The Letter of Intent outlines a mutually beneficial process for defining how the capabilities of UniCorp Biotech can partner with First Warning", adds Dr. Laszlo Horvath, CEO.
"We are planning for the CE Mark process early in 2013 to be followed by clinical validation and market entry of the First Warning Systems in select European markets", says Matt Benardis, First Warning Operations Manager. "Discussions with Dr. Horvath regarding UniCorp Biotech services to expedite certification and time-to-market have been encouraging", adds Benardis.
About First Warning Systems Process
Temperature readings of breast tissue create a dynamic cell chaos profile using 9,600 points of dynamic data which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS delivers a report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents and can be used by a primary care physician.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS's principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russia markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com. For more information, contact: Abbi Whittaker, The Abbi Agency. (775) 323-2977, firstname.lastname@example.org
About Unicorp Biotech
UniCorp Biotech was founded at the turn of the century. The owners desire to play a key role in the changing health care system of Europe in the area of quick and easy home access. Our company also manages (preparations, ethical permissions, monitoring) CRO projects within and outside of the European Union. We have the privilege to welcome among our customers many multinational companies acting in health care and distribution, such as Merck-Serono, Alexion, Gedeon Richter, PhamaNord, PhoenixPharma, HungaroPharma, Krka, Yamanouchi, Pliva, Tesco, Rossmann, Schlecker, Hungarian Military, National Police Headquarters. Our products are available in most pharmacies throughout Hungary and in some CEE countries. Since January of 2006, we have been the official Hungarian representatives of the Berlin-based Bayer Dermatology. UniCorp Biotech also provides information and preventive help for women, infants and Hungarians needing to be more informed, www.infertility.hu. & www.feminin.hu & www.abstinentia.hu provide assistance to those dealing with drug or other dependencies. For more information, contact: Dr. Laszlo Horvath, CEO, UniCorp Biotech Kft, H-1126 Budapest, Toth Lorincu.41., Hungary, Tel.: +36-1-393-5050, Fax: +36-1-393-5055.
SOURCE First Warning Systems, Inc.